G

Gemina Laboratories Ltd
CNSX:GLAB

Watchlist Manager
Gemina Laboratories Ltd
CNSX:GLAB
Watchlist
Price: 0.06 CAD Market Closed
Market Cap: CA$4.6m

Net Margin

-26 874.3%
Current
Improving
by 7 448%
vs 3-y average of -34 322.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-26 874.3%
=
Net Income
CA$-2.9m
/
Revenue
CA$10.9k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-26 874.3%
=
Net Income
CA$-2.9m
/
Revenue
CA$10.9k

Peer Comparison

Country Company Market Cap Net
Margin
CA
Gemina Laboratories Ltd
CNSX:GLAB
4.6m CAD
Loading...
US
Natera Inc
NASDAQ:NTRA
33.1B USD
Loading...
US
Exact Sciences Corp
NASDAQ:EXAS
19.4B USD
Loading...
US
Guardant Health Inc
NASDAQ:GH
14.3B USD
Loading...
FR
Biomerieux SA
PAR:BIM
12B EUR
Loading...
US
Caris Life Sciences Inc
NASDAQ:CAI
7.2B USD
Loading...
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
42.8B CNY
Loading...
KR
HLB Inc
KOSDAQ:028300
8.7T KRW
Loading...
CH
Siegfried Holding AG
SIX:SFZN
4.4B CHF
Loading...
IT
DiaSorin SpA
MIL:DIA
3.8B EUR
Loading...
UK
Abcam PLC
LSE:ABC
2.8B GBP
Loading...

Market Distribution

Lower than 96% of companies in Canada
Percentile
4th
Based on 4 909 companies
4th percentile
-26 874.3%
Low
-9 940 586.9% — -85.9%
Typical Range
-85.9% — 5.5%
High
5.5% — 60 777.6%
Distribution Statistics
Canada
Min -9 940 586.9%
30th Percentile -85.9%
Median -7.8%
70th Percentile 5.5%
Max 60 777.6%

Gemina Laboratories Ltd
Glance View

Market Cap
4.6m CAD
Industry
N/A

Gemina Laboratories Ltd. (Gemina) is a Canada-based biotechnology company. Gemina operates in the In Vitro Diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. It is engaged in biosensor and diagnostic services with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Gemina's technology drives testing platforms that are fast, affordable and accurate, and easily self-administered. Its development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. Gemina is focused on infectious respiratory diseases and the recovery from them. It has developed a first-generation technology (the Generation 1 Technology), which it has included within an initial demonstration product namely: a point-of-care lateral flow assay to test whether a person is infected with COVID-19 (the Legio-XTM COVID Rapid Antigen Test).

GLAB Intrinsic Value
0.01 CAD
Overvaluation 91%
Intrinsic Value
Price
G
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-26 874.3%
=
Net Income
CA$-2.9m
/
Revenue
CA$10.9k
What is Gemina Laboratories Ltd's current Net Margin?

The current Net Margin for Gemina Laboratories Ltd is -26 874.3%, which is above its 3-year median of -34 322.3%.

How has Net Margin changed over time?

Over the last 7 months, Gemina Laboratories Ltd’s Net Margin has increased from -44 353.2% to -26 874.3%. During this period, it reached a low of -44 353.2% on Apr 30, 2025 and a high of -26 874.3% on Dec 1, 2025.

Back to Top